GLP-1 for Hidradenitis Suppurativa: Weight Loss + Humira/Cosentyx Stacking

Hidradenitis suppurativa (HS) is the most obesity-associated chronic inflammatory skin disease we treat. The published population studies (Garg 2017, JAMA Dermatology^[6]) put adult US prevalence near 1%, with a strong female predominance, and the body-weight studies (Kromann 2014, Acta Dermato-Venereologica^[4]) put roughly three-quarters of patients above a BMI of 30. Adalimumab (Humira) is the original FDA-approved biologic for HS (Kimball 2016, PIONEER I/II^[1]); secukinumab (Cosentyx) and bimekizumab (Bimzelx) followed in 2023 and 2024 (SUNSHINE/SUNRISE^[2] and BE HEARD I/II^[3]). The newest adjunct is GLP-1 therapy: Strong and Driscoll's 2025 narrative review in the American Journal of Clinical Dermatology^[8] framed the question as “GLP-1 receptor agonists as the new frontier” for the obesity-plus-inflammation phenotype that dominates HS clinics. This article walks through what the evidence supports, what it does not, and the practical dermatology pathway when stacking Wegovy or Zepbound on top of an existing biologic.

The honest summary

• HS is obesity-anchored. Kromann 2014^[4] documented a dose-response between BMI and Hurley stage; ~75–80% of HS patients carry a BMI > 30, and severity correlates with weight class.
• Three biologics are FDA-approved. Adalimumab (Humira), secukinumab (Cosentyx), and bimekizumab (Bimzelx) all have phase 3 evidence on HiSCR (Hidradenitis Suppurativa Clinical Response) at week 12–16. Bimekizumab posted the highest absolute response in BE HEARD I/II^[3].
• Weight loss is disease-modifying. Sivanand 2020^[5] systematically reviewed the weight-loss-and-HS literature and reported consistent improvement in lesion counts and quality-of-life metrics across both dietary and bariatric cohorts.
• GLP-1 therapy stacks logically on top of biologics. Strong and Driscoll 2025^[8] argued the mechanism is plausible (mechanical reduction in intertriginous friction, plus systemic anti-inflammatory effects from adipose remodeling), and there are no known pharmacokinetic interactions between semaglutide or tirzepatide and the three approved biologics.
• Smoking is the other modifiable axis. Smoking cessation matters at least as much as weight loss for HS control; both should be addressed in parallel.

What HS actually is

Hidradenitis suppurativa is a chronic, recurrent, inflammatory follicular occlusion disorder that produces painful nodules, abscesses, draining sinus tracts, and scarring in apocrine-gland-rich skin: axillae, inframammary folds, groin, perianal region, and inner thighs. The Hurley staging system anchors clinical decision-making:

• Hurley I — isolated abscesses, no sinus tracts or scarring. Topical clindamycin plus benzoyl peroxide and short-course oral antibiotics are usually first-line.
• Hurley II — recurrent abscesses with sinus tract formation and scarring, but lesions are still separated by normal skin. Most biologic candidates sit here.
• Hurley III — diffuse or near-diffuse involvement, multiple interconnected tracts and abscesses. Combination therapy (biologic plus surgical deroofing or wide excision) is the standard approach.

The underlying pathophysiology is follicular hyperkeratinization and plugging, follicular rupture, secondary bacterial colonization, and a downstream cascade dominated by IL-17, TNF-alpha, and IL-1. The three approved biologics each block a different node in that cascade: adalimumab targets TNF-alpha, secukinumab targets IL-17A, and bimekizumab targets both IL-17A and IL-17F.

The obesity link is unusually strong

Garg 2017^[6] analyzed a US administrative-claims database and estimated adult HS prevalence at approximately 0.1%, with female-to-male ratios near 3:1 and peak prevalence in the third and fourth decades. Kromann 2014^[4] stratified 909 HS patients by BMI category and reported that disease severity (measured by lesion count and Sartorius score) increased monotonically with weight class. Roughly three-quarters of HS patients in published cohorts carry a BMI above 30; that fraction is closer to 40% in the general adult population.

The mechanistic story is twofold. First, the intertriginous anatomy of HS lesions makes friction, maceration, and humidity direct disease triggers; reducing body mass reduces the skin-on-skin surface area and the mechanical stress on follicular openings. Second, adipose tissue is itself a source of pro-inflammatory cytokines (TNF-alpha, IL-6, leptin), and reducing fat mass reduces the inflammatory tone that drives recurrent flares.

The three FDA-approved biologics, in order of approval

Adalimumab (Humira) was approved in 2015 on the strength of PIONEER I and PIONEER II (Kimball 2016, NEJM^[1]). The pooled HiSCR rate at week 12 was about 50% on adalimumab vs about 27% on placebo. Week-36 maintenance data showed sustained response in the patients who remained on therapy. Dosing is 160 mg loading at week 0, 80 mg at week 2, then 40 mg weekly thereafter.

Secukinumab (Cosentyx) was approved for HS in 2023 based on SUNSHINE and SUNRISE (Kimball 2023, Lancet^[2]). The two identical phase 3 trials randomized 1,084 patients combined; HiSCR at week 16 was approximately 42–46% on the every-2-week and every-4-week dosing regimens vs 31–34% on placebo. Week-52 data demonstrated durable response. Dosing is 300 mg subcutaneously weekly for five weeks, then 300 mg every 2 or 4 weeks.

Bimekizumab (Bimzelx) was approved for HS in 2024 based on BE HEARD I and BE HEARD II (Kimball 2024, Lancet^[3]). The pooled HiSCR50 at week 16 was approximately 48–52% on bimekizumab vs 32% on placebo; week-48 data on the higher-bar HiSCR75 endpoint were favorable, with roughly one-third of bimekizumab-treated patients reaching that threshold. Dosing is 320 mg subcutaneously every 2 weeks through week 16, then every 2 or 4 weeks.

Infliximab is used off-label, typically in adalimumab failures. Anakinra and ustekinumab have weaker evidence and are rarely first-line in 2026.

Weight loss as disease modification

Sivanand 2020 (Journal of Cutaneous Medicine and Surgery^[5]) systematically reviewed the weight-loss and dietary-intervention literature in HS. Across the bariatric cohorts and the dietary cohorts (including elimination diets and brewer's-yeast avoidance), the consistent finding was reduction in lesion counts and improvement in patient-reported outcomes after a ~15% body-weight reduction. The bariatric cohorts in particular showed substantial improvement in Hurley stage and a meaningful fraction of remission cases.

Metformin has independent disease-modifying evidence. Petrasca 2023 (British Journal of Dermatology^[7]) reported beneficial effects of metformin in HS through both weight-mediated and direct anti-inflammatory mechanisms (AMPK activation, IL-17 pathway modulation). That work is part of why the question of GLP-1 therapy in HS is reasonable to ask: weight loss alone improves HS, and an agent that also has direct anti-inflammatory signals could plausibly add to the biologic effect.

GLP-1 medications: what we know and what we don't

Strong and Driscoll 2025 (American Journal of Clinical Dermatology^[8]) is the canonical narrative review on GLP-1 receptor agonists in HS. The authors framed the rationale around three convergent observations. First, the obesity rate in HS is high enough that an effective weight-loss medication addresses a near-universal modifiable risk factor. Second, GLP-1 receptors are expressed on immune cells, and animal and early-phase human data show reductions in circulating TNF-alpha, IL-6, and CRP independent of weight loss. Third, the mechanical reduction in intertriginous surface contact from even moderate weight loss can plausibly reduce flare frequency in axillary and inguinal disease.

Prospective controlled trials of semaglutide or tirzepatide in HS have not yet read out. The current evidence base is the narrative review, retrospective dermatology-clinic series, and the established weight-loss and biologic literature. The practical position, which Strong and Driscoll 2025^[8] endorse, is that GLP-1 therapy is reasonable as an adjunct in HS patients who already meet weight-loss medication eligibility, not a replacement for biologic therapy in moderate-to-severe disease.

Magnitude: HiSCR response rates across interventions

The practical dermatology pathway

1. Confirm Hurley stage and baseline severity. Photograph affected sites, record lesion counts, and calculate the modified Sartorius score if available. This is your baseline for response assessment at week 12–16.
2. Address smoking and weight in parallel. Smoking cessation has at least as much disease-modifying weight as weight reduction; do not pick one. Refer to a tobacco cessation clinic and, separately, to obesity medicine if the patient has a BMI ≥ 30 or ≥ 27 with weight-related comorbidity.
3. Start the biologic appropriate to severity. Hurley II with active inflammation is the typical biologic entry point. Adalimumab remains a reasonable first choice (longest real-world experience, broadest insurance coverage). Bimekizumab is the highest-response option in patients who fail or only partially respond to adalimumab. Secukinumab is a reasonable second-line in adalimumab failures who cannot access bimekizumab.
4. Layer GLP-1 therapy when eligible. Semaglutide 2.4 mg or tirzepatide 5–15 mg can be started in parallel with the biologic. Slow titration (4-week steps) helps with the GI side effects that are especially bothersome when patients are also managing painful flares. There are no known pharmacokinetic interactions with adalimumab, secukinumab, or bimekizumab.
5. Plan surgery for residual fixed disease. Even with optimal biologic and weight-loss therapy, fixed sinus tracts and scarring do not resolve medically. Wide local excision, deroofing, or CO2 laser de-roofing is the definitive intervention for fixed Hurley III disease. Time surgery after a meaningful weight-loss response when possible — wound healing improves and recurrence rates drop.
6. Reassess at week 16 and again at week 36. Use HiSCR or the modified Sartorius score. Patients who do not reach HiSCR at week 16 on adalimumab should be considered for bimekizumab or secukinumab.

Practical considerations on GLP-1 + biologic stacking

• Hydration matters more than usual. Intertriginous HS lesions are sensitive to dehydration and to friction; GLP-1 therapy reduces oral intake and can worsen dehydration if patients are not deliberately drinking fluids. Counsel explicitly.
• Protein intake is the second priority. HS patients on biologics are already at modestly elevated infection risk; preserving lean mass during GLP-1-mediated weight loss matters. 1.6–2.0 g/kg of current body weight per day is the published target.
• Track flares against dose escalation. Some patients report a transient flare during the steep phase of GLP-1 weight loss, plausibly mediated by adipose remodeling and cytokine release. Slowing the dose ladder (an extra 4 weeks at each step) is reasonable.
• Insurance is generally favorable. HS biologics are covered under specialty pharmacy benefits with prior authorization; GLP-1 coverage for obesity has improved substantially through 2025–2026 but remains inconsistent. Document the obesity-plus-HS phenotype on the prior authorization to maximize approval odds.
• Pregnancy planning is mandatory. Adalimumab is the most pregnancy-data-rich biologic and is generally considered acceptable in pregnancy; secukinumab and bimekizumab have less data and are usually held. Semaglutide and tirzepatide are not used in pregnancy and should be stopped at least two months before planned conception.

Related research and tools

• GLP-1 for psoriasis and eczema — the parallel inflammatory-skin question, also with TNF and IL-17 biologic stacking
• GLP-1 in SLE, lupus, and rheumatoid arthritis — the broader autoimmune adjunct question
• GLP-1 and smoking cessation — the other modifiable axis in HS
• GLP-1, cortisol, and stress-driven inflammation — the HPA-axis contribution to inflammatory skin disease
• Preventing lean-mass loss on a GLP-1 — protein and resistance-training protocol that matters in patients already on a biologic
• GLP-1 protein calculator — daily protein target by current body weight

Important disclaimer. This article is educational and does not constitute medical advice. Hidradenitis suppurativa management requires individualized dermatology care; biologic initiation, dose adjustments, and surgical planning belong with a qualified specialist. GLP-1 therapy in HS patients on biologics has not been studied in randomized controlled trials and the projected combined response shown in the magnitude chart is indicative only. Pregnancy planning, infection risk monitoring, and surgical timing should be coordinated across dermatology, obesity medicine, and obstetrics where applicable. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if a randomized controlled trial of a GLP-1 medication in HS reads out.